Daymark Health Builds Clinical Advisory Board

Why It Matters

The board’s multidisciplinary expertise positions Daymark to accelerate its innovative, patient‑centric model, potentially reshaping oncology delivery and influencing payer adoption of value‑based contracts.

Key Takeaways

• Daymark forms advisory board of top oncology experts
• Board includes patient advocates, policymakers, and health‑care executives
• Advisory board supports Daymark’s value‑based, full‑risk cancer care model
• Company raised $31.5 million total funding to date
• Board meetings scheduled quarterly to guide strategy and implementation

Pulse Analysis

Daymark Health entered the oncology market in April 2025 with a bold, full‑risk, value‑based care platform that integrates clinical, mental‑health and social services for cancer patients. Backed by $31.5 million in seed and Series A capital, the company partners with regional payers to deliver virtual and in‑home support, aiming to improve outcomes while containing costs. This model aligns with a broader industry shift toward bundled payments and outcomes‑based reimbursement, where providers are incentivized to keep patients healthier rather than simply delivering services.

The newly formed Clinical Advisory Board adds significant credibility and strategic depth to Daymark’s mission. Comprising high‑profile figures such as Memorial Sloan Kettering’s chief medical officer, a former U.S. Secretary of Veterans Affairs, and seasoned patient advocates, the board blends clinical insight with policy and payer perspectives. Their quarterly convenings are designed to refine care pathways, address regulatory challenges, and ensure that patient voices remain central—a critical factor as health‑care consumers demand more personalized, transparent experiences.

For investors and industry observers, Daymark’s advisory board signals a commitment to scaling its model through evidence‑based innovation. By leveraging the board’s expertise, the company can accelerate data collection, validate its outcomes, and negotiate broader payer contracts. If successful, Daymark could become a template for integrated, value‑based oncology services, prompting larger health systems and startups alike to adopt similar patient‑first, risk‑sharing frameworks.